About Akero Therapeutics

Akero Therapeutics (NASDAQ:AKRO) is a biotechnology firm dedicated to developing innovative treatments for serious metabolic diseases, with a sharp focus on non-alcoholic steatohepatitis (NASH). At the heart of its operations is a drive to address the urgent needs of patients facing these life-threatening conditions, through the advancement of its lead product candidate, EFX, a novel therapy designed to ameliorate the effects of NASH. The company's projects span various stages of clinical development, aiming to demonstrate EFX's potential in improving liver health and providing a much-needed solution in the NASH treatment landscape. Akero Therapeutics' objectives are centered on pushing the boundaries of scientific discovery to improve patient care, driving forward clinical trials to bring their therapeutic solutions closer to market approval, and ultimately changing the treatment paradigm for metabolic diseases.

Snapshot

Public USOwnership

2017Year founded

57Employees

South San Francisco, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

South San Francisco, US

Products and/or services of Akero Therapeutics

Efruxifermin (EFX) for NASH treatment: A FGF21 analogue undergoing clinical trials aimed at addressing the root causes of non-alcoholic steatohepatitis (NASH).
EFX for serious metabolic disorders: Exploring EFX's potential in treating a range of metabolic diseases beyond NASH, capitalizing on its insulin-sensitizing and lipid-regulating effects.
Combination therapies with EFX: Investigating EFX in combination with other therapies to enhance treatment outcomes for NASH and potentially other metabolic conditions.
Pipeline expansion: Focusing on expanding the drug pipeline by exploring new molecular targets and pathways relevant to NASH and metabolic diseases.
Disease diagnostics and patient identification: Developing diagnostic tools and algorithms to better identify candidates for NASH treatments, improving clinical trial enrollment and precision medicine approaches.
Patient support and disease education: Offering comprehensive support and educational resources for patients diagnosed with NASH and metabolic disorders, emphasizing treatment adherence and lifestyle modification.

Akero Therapeutics executive team

Dr. Andrew Cheng M.D., Ph.D.President, CEO & Director
Dr. Jonathan M. Young J.D., Ph.D.Co-Founder, Executive VP, COO & Secretary
Mr. William R. White J.D.Executive VP, CFO, Treasurer & Head of Corporate Development
Mr. Scott A. GangloffChief Technical Officer
Ms. Catriona YaleExecutive VP & Chief Development Officer
Dr. Timothy Rolph Ph.D.Co-Founder & Chief Scientific Officer
Mr. Thomas RossSenior VP & Head of Legal
Mr. John J. SchembriSenior VP & Head of Finance
Mr. Patrick LamySenior Vice President of Commercial Strategy